NASDAQ: VRTX

Vertex Pharmaceuticals Incorporated

Healthcare • Biotechnology • www.vrtx.com

$472.01 $-7.86 (-1.81%)

As of Feb 25, 2:33 PM UTC

Annual Financial Statements for Vertex Pharmaceuticals Incorporated

Annual Quarterly

This table shows Vertex Pharmaceuticals Incorporated's annual financial data. All values are USD millions unless otherwise specified.

METRIC	2019 2019-12-31	2018 2018-12-31	2017 2017-12-31	2016 2016-12-31
Revenue	4,163	3,048	2,489	1,702
Cost of Revenue	548	410	275	210
Gross Profit	3,615	2,638	2,214	1,492
Operating Expenses	2,413	1,974	1,821	1,481
Operating Income	1,198	635	123	10
Interest Expense	59	34	69	81
Income Tax Expense	218	-1,487	-107	17
Net Income	1,177	2,097	263	-112

EBITDA	1,560	707	103	75
Basic EPS	$4.58	$8.25	$1.06	-$0.46
Diluted EPS	$4.51	$8.09	$1.04	-$0.46

METRIC	2019 2019-12-31	2018 2018-12-31	2017 2017-12-31	2016 2016-12-31
Operating Activities
Cash from Operations	1,569	1,270	845	236
Investing Activities
Capital Expenditures	-75	-96	-259	-57
Cash from Investing	-1,235	-202	-438	104
Financing Activities
Dividends Paid	—	—	—	—
Stock Repurchased	-192	-350	0	0
Cash from Financing	127	-71	68	133

Free Cash Flow	1,494	1,175	586	180

METRIC	2019 2019-12-31	2018 2018-12-31	2017 2017-12-31	2016 2016-12-31
Assets
Cash & Equivalents	3,109	2,650	1,665	1,184
Short-term Investments	699	518	423	251
Accounts Receivable	634	410	386	235
Inventory	168	124	112	78
Total Current Assets	4,823	3,843	2,649	1,832
Total Assets	8,318	6,246	3,546	2,894
Liabilities
Accounts Payable	88	111	74	61
Short-term Debt	0	0	0	300
Total Current Liabilities	1,335	1,120	807	793
Long-term Debt	0	0	0	0
Total Liabilities	2,233	1,811	1,504	1,559
Shareholders' Equity
Total Stockholders' Equity	6,085	4,435	2,029	1,157

Total Debt	662	587	606	841